How many investments has Novartis Venture Fund made?

Novartis Venture Fund has 67 tracked investments, 4 of which have exited, including 8 dated in the last 24 months.

What stage does Novartis Venture Fund invest at?

Novartis Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.

What is Novartis Venture Fund's typical check size?

Novartis Venture Fund typically writes checks of $5M – $25M.

What sectors does Novartis Venture Fund focus on?

Novartis Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Novartis Venture Fund located?

Novartis Venture Fund is headquartered in Basel, CH.

Does Novartis Venture Fund lead rounds?

Yes, Novartis Venture Fund leads investment rounds.

Who does Novartis Venture Fund co-invest with?

Novartis Venture Fund most often shares deals with Pfizer Venture Investments, SV Health Investors, M Ventures, among 83 tracked co-investors.

Novartis Venture Fund

Corporate VC

Basel · Seed–Growth · 21 people tracked

Also known as Novartis Venture

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Novartis Venture Fund

Paths you didn't know you had: your email and LinkedIn already hold routes to the Novartis Venture Fund team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Novartis Venture Fund backs innovative life science companies with the aim of fostering innovation, driving meaningful patient benefit, and generating strong returns. It focuses on biotechnology and biopharmaceutical companies developing novel therapeutics and platforms addressing unmet patient needs across the healthcare spectrum. The fund invests in both early-stage startups and later-stage companies, taking a hands-on approach by working closely with boards and management teams to deliver clinical impact. Operating from bases in Basel, Switzerland and Cambridge, Massachusetts, its team brings deep expertise in drug development across a range of therapeutic areas and drug modalities.

Invests inBiotech Digital Health Healthtech Medical Devices Europe North America Switzerland United States

Source: firm website, verified Sep 27, 2026.

Leave your own feedback

Stage

Seed–Growth

Check

$5M – $25M

Basel, CH

Leads rounds

Leads

Instruments

Equity

Founded

1996

Last 12 months

3 investments

AUM

$750M

Tracked investments

IPOs

Acquisitions

Team · 21 people

from the firm's website & curated & public directories

Bart Dzikowski· Managing Director, Head of Transactions & Legal· Basel, Switzerlandin

Bart Dzikowski is a Managing Director at the Novartis Venture Fund, where he heads Transactions & Legal. Before this role he held senior positions in Novartis' Transactions groups, which he joined in 2009, and earlier worked as a VP in investment banking at Bank of America/Merrill Lynch and as a transactions attorney at Allen & Overy in New York. He holds Juris Doctor and Civil Law degrees from McGill Law School and is a member of the New York State Bar.

bart.dzikowski@novartis.com

Florian Müellershausen· Managing Director· Basel, Switzerlandin

Florian Muellershausen, PhD, is a Managing Director at the Novartis Venture Fund based in Basel, Switzerland. Before joining the fund, he served as a Scientific Manager for the R&D Committee of the Novartis Board of Directors and held drug discovery roles in Novartis R&D, including Laboratory Head in target discovery and Translational Medicine Expert in autoimmunity. He holds an MSc in Biochemistry from Free University Berlin, a PhD in Biochemistry from Ruhr University Bochum, and completed postdoctoral training at Novartis in Switzerland.

florian.muellershausen@novartis.com

Laura Brass· Managing Director· Cambridge, MA, USAin

Laura Brass is a Managing Director at the Novartis Venture Fund in Cambridge, MA, where she invests in biotechnology and biopharma companies. Before joining NVF, she was a Managing Director at MPM Capital and part of the founding management team at TriNetX, where she served as SVP of Business Development. Earlier in her career she held roles in business development and IP strategy and was CEO of Aferon, an early-stage antiviral startup. She holds a BA in Philosophy and BS in Biochemistry from the University of Missouri-Columbia, plus a PhD in Molecular Genetics and Cell Biology and an MBA, both from the University of Chicago.

laura.brass@novartis.com

Marianne Uteng· Managing Director· Basel, Switzerlandin

Marianne Uteng, PhD, is a Managing Director at Novartis Venture Fund in Basel. She previously worked in Novartis Global Drug Development and its Pre-Clinical Safety Department, leading teams on safety assessments for early and late-stage programs, and supported Novartis BD&L Search & Evaluation while building collaborations with biotech companies and academia. She holds an MSc in Biochemistry from the University of Oslo and a PhD in Molecular Biology, Cell Biology & Biophysics from a joint EMBL–University of Oslo program.

marianne.uteng@novartis.com

Michal Silverberg· Managing Director· Boston, Massachusettsin

michal.silverberg@novartis.com

Adam Cotton· Principal· Cambridge, MA, USAin

Adam Cotton is a Principal at the Novartis Venture Fund based in Cambridge, MA. Before joining the fund, he conducted antibody engineering research in the labs of Jim Wells and Ian Seiple, and he is a scientific co-founder of Epi Biologics. He helped translate both Rezo Therapeutics and HYKU Biosciences from academic labs into companies. He holds a PhD in Chemistry & Chemical Biology from UCSF, a BA in Chemistry from Harvard, and an MBA from the University of New Mexico. At the fund he invests in life science companies and sits on or observes the boards of companies including GentiBio, Mediar Therapeutics, Sidewinder Therapeutics, and Seawolf.

Beat Steffen· Principal· Basel, Switzerlandin 𝕏

Beat Steffen is a Managing Director at the Novartis Venture Fund. He previously held commercial roles at Novartis Pharmaceuticals in the US and Switzerland, launching products in the cardiovascular area, and earlier worked at McKinsey & Company in Zurich with pharmaceutical clients. He is a Swiss-trained physician specializing in cardiovascular surgery and intensive care and holds an MBA from INSEAD.

beat.steffen@novartis.com

Mathias Frederiksen· Principal· Basel, Switzerlandin

Mathias Frederiksen is a Principal at the Novartis Venture Fund, based in Basel. Before joining NVF, he was a group leader in Novartis R&D, where his work covered neuroscience-focused medicinal chemistry, chemical genomics, and target discovery, with a focus on epigenetic dysregulation in disease, and he served on the portfolio management and strategy team. He holds a BSc in Chemistry from Mount Allison University, a PhD in Chemistry from Imperial College London, and completed a postdoctorate at Stanford University.

Campbell Murray· Cambridge, Massachusettsin

Campbell Murray is a Director at Lighthouse Pharmaceuticals and is affiliated with Double Point Ventures. Murray works in venture capital investment and has experience in the biopharma and life sciences industries.

Florent Gros· Switzerland

Florent Gros is a Kauffman Fellow, a member of Class 12 of the two-year venture capital leadership program run by Kauffman Fellows. The program's member directory lists them at Novartis Venture Fund in Switzerland.

Anja Koenig· Global Head of NVF· Basel, CHin

Anja Koenig, who holds a PhD in Physics from Cornell University, leads the Novartis Venture Fund and was previously a Managing Director at the fund covering Switzerland, the UK, the rest of Europe, and Asia/Pacific. Before joining NVF, she was an Associate Partner at McKinsey and Company in New York, working with healthcare companies across the US, Europe, and emerging markets. She is involved in the Swiss startup ecosystem and serves on the board of Sensirion, a publicly listed Swiss engineering company.

anja.koenig@novartis.com

Christoph Meier· Prof. Christoph A. Meier, MD· Zurich, Switzerland

Christoph A. Meier, MD, is Head of the Department of Internal Medicine at the University Hospital Zurich and Professor at the Medical Faculty of the University of Geneva. He previously served as Chief Medical Officer and deputy CEO at the University Hospital Basel, and held leadership roles in internal medicine and endocrinology at Triemli Hospital in Zurich and the University Hospital Geneva. He earned his medical degree from the University of Basel and completed fellowships at the NIH, Brigham and Women's Hospital, and Massachusetts General Hospital/Harvard Medical School.

Elaine Jones· Dr.

Elaine Jones holds a PhD and has over 20 years of experience as a life science-focused venture capitalist. She was previously Vice President of Venture Capital at Pfizer Ventures, a General Partner at EuclidSR Partners, and began her investing career at S.R. One, the corporate fund of GlaxoSmithKline; earlier she was Director of Scientific Licensing and a research scientist at SmithKline Beecham. She earned a BS in Biology from Juniata College and a PhD in Microbiology from the University of Pittsburgh, with postdoctoral research at the National Institutes of Health.

Elena Battistello· Analyst· Zurich, Switzerlandin 𝕏

Elena Battistello is an Analyst at the Novartis Venture Fund. Before joining the firm, she was a postdoctoral fellow at the New York University School of Medicine working on cancer immunotherapies, and prior to that she conducted research on targeted therapy and immunotherapy for blood tumors at EPFL. She holds a BSc from Padua University, a double MSc from Paris-Diderot University and Padua University, and a PhD from EPFL.

Fiona H. Marshall· President of Biomedical Research, Novartis· Cambridge, Massachusetts, United Statesin

Fiona H. Marshall holds a PhD and serves as President of Biomedical Research at Novartis and sits on the company's Executive Committee, having joined in 2022. She previously led Discovery Sciences, Preclinical Development and Translational Medicine at MSD (Merck & Co.), and before that co-founded Heptares Therapeutics, where she was Chief Scientific Officer through its acquisition by Sosei. Earlier roles included Director of Molecular Pharmacology at Millennium Pharmaceuticals and senior positions at GSK; she earned a BSc in Biochemistry from the University of Bath and a PhD in Neuroscience from the University of Cambridge.

Michael Gilman· Dr.

Michael Gilman, PhD, is a scientist, general manager, biotech executive and entrepreneur. He founded and led Padlock Therapeutics (acquired by Bristol-Myers Squibb in 2016) and Stromedix (acquired by Biogen Idec), and held senior research and pipeline roles at Biogen Idec and ARIAD Pharmaceuticals. Earlier he was on the scientific staff at Cold Spring Harbor Laboratory; he holds a PhD in Biochemistry from UC Berkeley and an SB in Life Science from MIT.

Michael Hengartner· President of the ETH Board and Chairman of the Executive Committee of the ETH Domain

Michael Hengartner, PhD, MBA, is President of the ETH Board and Chairman of the Executive Committee of the ETH Domain. He previously served as Rector of the University of Zurich (2014-2020) and President of swissuniversities (2016-2020). He studied biochemistry at the Université Laval, earned his PhD at MIT in 1994, led a research group at Cold Spring Harbor Laboratory, and later held a professorship at the University of Zurich, focusing his research on the molecular basis of apoptosis.

Michelle Ma· Analyst· Boston, Massachusettsin

Michelle Ma is an Associate at the Novartis Venture Fund based in Cambridge, MA. Before joining the firm, she conducted research in Eric Fischer's lab, where her thesis examined mechanisms of protein degraders using biochemistry and structural biology. She earned a BA in Molecular and Cell Biology from UC Berkeley and a PhD in Biochemistry from Harvard University.

Mukul Mehta· Chief Financial Officer of Novartis

Mukul Mehta was appointed Chief Financial Officer of Novartis in March 2026, following more than 20 years in finance roles across the company's Commercial, Development, Business Services, and Corporate Finance functions since 2003. Before that role he oversaw Business Planning & Analysis, Digital Finance, and Tax, and earlier worked in India's heavy engineering and banking sectors. He holds an MBA from INSEAD and a bachelor's degree in Electrical Engineering from PEC Chandigarh, India.

Samantha Guinn· Analyst· Cambridge, MA, USAin

Samantha Guinn, PhD, is an Analyst at the Novartis Venture Fund. She was previously an Associate at Flagship Pioneering, where she worked on venture hypotheses, therapeutic concepts, and landscaping assessments, and earlier conducted research in the lab of Dr. Elizabeth Jaffee focused on cancer-associated fibroblast cellular crosstalk in pancreatic cancer. She holds a BSc from Colorado State University, an MMSc in Immunology from Harvard Medical School, and a PhD in Immunology from Johns Hopkins University School of Medicine.

Shreeram Aradhye· President, Development and Chief Medical Officer, Novartis; Member of the Novartis Executive Committee· Basel, Basel, Switzerlandin

Shreeram Aradhye, MD, is President of Development and Chief Medical Officer at Novartis and a member of its Executive Committee, overseeing advancement of the company's pipeline of investigational medicines. He first joined Novartis in 1999 and held leadership roles across the US, Switzerland, Germany, and India before spending several years at US biotechnology companies, including leading development of clinical-stage RNAi assets at Dicerna Pharmaceuticals, then rejoined Novartis in May 2022. Earlier he was a transplant nephrologist, attending physician, and assistant professor of medicine at the University of Pennsylvania, and completed his medical training at the All India Institute of Medical Sciences in 1989.

Founder mafia

4 people who came through Novartis Venture Fund went on to found or lead other companies.

Huw NashConsultantFounded Aileron Therapeutics +1 Steve TregayManaging DirectorFounded Compass Therapeutics Adam CottonPrincipalFounded Epi Biologics Rahul BallalKauffman Fellow (Class 15)Founded Mediar Therapeutics

What they invest in

from 57 of 67 portfolio companies

Biotech ×52Healthtech ×30Medical Devices ×21Deep Tech ×13Digital Health ×6AI & Machine Learning ×3Longevity ×3Enterprise Software ×2

HQs:United States×28United Kingdom×5Switzerland×4France×2Netherlands×2Australia×1

Who they back

founder profiles across 14 portfolio companies

50%

solo founders

7 of 14 mapped founding teams

17%

repeat founders

of 12 founders with career history

~4 yrs

old at investment

median across 11 dated deals

Founding team size:solo founder×72 founders×64+ founders×1

What their founders studiedfrom 11 founders with field-of-study data

Life Sciences ×8Medicine ×4Chemistry ×2

Where their founders worked beforefrom 12 founders with career history

Alzheimer's Research UK ×2GlaxoSmithKline ×2Pfizer ×2UCL ×2

Investments · 67 tracked

founders shown can be your intro path

By year:2025 · 7 2024 · 5 2023 · 2 2022 · 3 2021 · 5 2020 · 7 2019 · 2 2018 · 2 2016 · 1 2015 · 1 2014 · 2 2012 · 244 dated

Adicet Bioadicetbio.comNASDAQ: ACET

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in

Board Jonathan Silverstein(Director)in Carl Gordon(Director)inFlorent Gros(Director)

Co-investorsForesite Capital OrbiMed Pontifax Venture Capital Quan Capital aMoon PureTech Health

Aileron Therapeuticsreintx.com inNASDAQ: RNTX

Aileron Therapeutics is a clinical-stage biopharmaceutical company developing peptide and protein-based therapies for rare lung and fibrosis diseases.

BiotechCambridge, US

Manuel Aivado(Executive Officer)inBrian Windsor(President and Chief Executive Officer; Director)in

BoardCaleb Winder(Director)inSeth L. Harrison(Director)Reinhard J. Ambros(Director)Joseph A. Yanchik III(Executive Officer, Director)in

Co-investorsExcel Venture Management

Bicyclebicycletherapeutics.com in 𝕏NASDAQ: BCYCSeed · Oct 2009

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

Gregory Winter(Director)in NIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in

Co-investorsAhren Innovation Capital Astellas Venture Management LLC Cambridge Innovation Capital Dementia Discovery Fund Longwood Fund Ridgeback Capital +4 more

Aravaxaravax.com.au inJan 2024 · $66M✓ verified

Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.

BiotechHealthtechMedical DevicesMelbourne, AU

Sara Prickett(Co-founder)in

Co-investorsBreakthrough Victoria Tenmile UniSeed Pty Ltd.

GentiBiogentibio.com in 𝕏Aug 2020✓ verified

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)inDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)inTom Wickham(Chief Scientific Officer)

Co-investorsOrbiMed JDRF T1D Fund RA Capital

Granite Biogranitebio.com inApr 2025 · $100M✓ verified

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

Patrick Loustau(President and Chief Executive Officer)in

Co-investorsSanofi Ventures Forbion Versant Ventures

HYKU Bioscienceshykubiosciences.com inDec 2025✓ verified

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.

BiotechDeep TechMedical DevicesBurlington, US

KLEEM CHAUDHARY(Executive Officer, Director, Promoter)inKu-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)

BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)in LAURA TADVALKAR(Director)in

Co-investorsDroia Ventures Eisai Innovation, Inc.RA Capital

NRG Therapeuticsnrgtherapeutics.com inSeries B · Sep 2025 · $68M✓ verified

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.

BiotechHealthtechLongevity

Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)in Claus Sundgreen(Chief Medical Officer)in Paul Thompson(CDO)in

BoardJonathan Savidge(Independent Non Executive Chair)

Co-investorsCriteria Bio Ventures SV Health Investors British Business Bank M Ventures Dementia Discovery Fund Omega Funds

ONL Therapeuticsonltherapeutics.com in✓ verified

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

David Zacks(Co-Founder & Chief Scientific Officer)in David Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)in Jeffrey A Jamison(Executive Officer)in

Board Aaron Fletcher(Director)in

Co-investorsExSight Ventures Invest Michigan Visionary Ventures Bios Partners InFocus Capital Partners, LLC Johnson & Johnson Innovation – JJDC +3 more

RhyGaze AGrhygaze.com inSeed · Jul 2024 · $11M✓ verified

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.

BiotechDigital HealthMedical DevicesBasel, CH

Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)in Katherine High(CEO)in

Co-investorsARCH Venture Partners BioGeneration Ventures F-Prime Capital GV (Google Ventures)

Soteria Biotherapeutics, Inc.soteriabiotherapeutics.com inMay 2021✓ verified

Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.

BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)in Zachary Hill(Executive Officer, Director)in

BoardNisha Marathe(Director)David Allison(Director)in Keno Gutierrez(Director)in

Co-investors5AM Ventures Roche Venture Fund Versant Ventures BioGeneration Ventures Westlake Village BioPartners

Splice Biosplice.bio in 𝕏Series A · Feb 2022 · $57M✓ verified

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Co-investorsAsabys Partners Roche Venture Fund Sanofi Ventures Ysios Capital Criteria Bio Ventures New Enterprise Associates (NEA)+3 more

Vivet Therapeuticsvivet-therapeutics.com in 𝕏✓ verified

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHealthCap Kurma Partners Roche Venture Fund Ysios Capital Columbus Venture Partners Eurazeo +1 more

Mediar Therapeuticsmediartx.com inNov 2022

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)in Rahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Board seat Anja Koenig· per SEC Form D

Co-investorsAgent Capital Gimv Longwood Fund Mission Biocapital Ono Venture Investment, Inc.Pfizer Venture Investments +5 more

Akouosakouos.com inAug 2018 · $50M

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in

Board Ed Mathers(Director)in Kush Parmar(Director)in

Co-investors5AM Ventures EcoR1 Capital New Enterprise Associates (NEA)Pivotal Life Sciences RA Capital Sofinnova Ventures +2 more

Alestaalestatherapeutics.com in

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.

BiotechHealthtech

Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in

Co-investorsDroia Ventures Frazier Life Sciences RV Invest GmbH Frazier Healthcare Partners MPM BioImpact RTW Investments L.P.+1 more

Amphista Therapeuticsamphista.com in 𝕏Series B · Mar 2021 · $53M

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)in Giles Brown(Executive VP Drug Discovery)in

Co-investorsAdvent Life Sciences SV Health Investors Dementia Discovery Fund European Investment Fund Forbion Gilde Healthcare +2 more

Anaveonanaveon.com inSeries A · Feb 2019 · $35M

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsPfizer Venture Investments Pontifax Venture Capital Forbion

Artios Pharmaartios.com in 𝕏Series B · Nov 2025 · $115M

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsAndera Partners Dementia Discovery Fund M Ventures Pfizer Venture Investments RA Capital Sofinnova Partners +6 more

Arvadaarvadatx.com

Arvada Therapeutics is a biotechnology company focused on drug development for rare and degenerative diseases, working across preclinical research and clinical stages.

BiotechHealthtechLongevity

ShiYin Foo(Founder and CEO)Ryan Tyler(Co-founder and SVP of Preclinical Research)

Co-investorsPillar VC

AstronauTX Ltdastronautx.bio inSeries A · Oct 2023 · $59M

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.

BiotechDeep TechHealthtechLongevityMedical Devices

Jane Rhodes(Chief Executive Officer)inMagnus Ivarsson(Chief Scientific Officer)inHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in

Co-investorsDementia Discovery Fund MPM BioImpact SV Health Investors UCL Technology Fund AlbionVC

Atalantaatalantatx.com in 𝕏Jan 2025 · $97M

Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology.

BiotechDeep TechHealthtechMedical Devices

Co-investorsF-Prime Capital RiverVest Venture Partners Sanofi Ventures abrdn plc EQT Life Sciences

Atalantaatalanta.fr

Atalanta is a web agency that designs and builds custom websites, mobile applications (iOS/Android), bespoke CRM tools, and provides UX/UI design and SEO services.

Developer ToolsMarketing TechSaaSAngers, FR

Antoine Chérel(Founder)

Co-investorsAbstract Ventures

Averna Therapeuticsavernatx.com inSeries A · Jun 2024 · $85M

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechHealthtechMedical DevicesWatertown, US

Richard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)

BoardRoy Amariglio(Director)Nick Olsen(Director)in Stephen Squinto(Director)inMichal Silverberg(Director)in

Co-investorsDeep Insight Delos Capital OrbiMed ARC VENTURES Insight Partners

CatalYmcatalym.com inSeries C · Nov 2020 · $52M

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)in Stefan Ries(Chief Scientific Officer and Head of Munich Site)in Andrea Goddard(Chief Technical Officer)in

Co-investorsJeito Capital Bioqube Ventures Forbion Bayern Kapital BioGeneration Ventures Canaan Partners +2 more

Citryllcitryll.com inSeries B · Dec 2024 · $90M

Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.

BiotechHealthtechMedical DevicesOss, NL

Renato Chirivi(Co-founder (former CSO))in

BoardPaul Peter Tak(Chair of the Board)

Co-investorsBioGeneration Ventures Pureos Bioventures Seventure Partners Forbion Johnson & Johnson Innovation – JJDC BOM +1 more

Enterprise Therapeuticsenterprisetherapeutics.com in 𝕏

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

John Ford(Co-founder)in Martin Gosling(Founder)in

Co-investorsEpidarex Capital Versant Ventures Forbion IP Group Panakes Partners

Epi Biologicsepibiologics.com in

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

Board Samuel Bjork(Director)in Alexandra Cantley(Director)in Seiji Miyahara(Director)in

Co-investorsAvego BioScience Capital GV (Google Ventures)Mission Biocapital Roche Venture Fund Samsara BioCapital Taiho Ventures, LLC +4 more

Epsilogenepsilogen.com inSeries B · Mar 2022 · $41M

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.

BiotechHealthtech

Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)in Nick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)

Co-investors3B Future Health Fund AlbionVC BioGeneration Ventures Epidarex Capital Global BioAccess Fund UCL Technology Fund

Exo Therapeuticsexo-therapeutics.com in 𝕏

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David Liu inAlan Saghetelian

Co-investorsNewpath Partners CRV (Charles River Ventures)Nextech Invest Raptor Group Samsara BioCapital Biotechnology Value Fund +1 more

F2Gf2g.comSep 2012 · $30M

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAdvent Life Sciences Aisling Capital AMR Action Fund Astellas Venture Management LLC Brace Pharma Sofinnova Partners +4 more

Faze Medicines inDec 2020

BiotechCambridge, US

Ed Freedman(Executive Officer, Director)

Board Cary Pfeffer(Executive Officer, Director)in Robert Tepper(Director)in Charles Homcy(Director)

Co-investorsThird Rock Ventures

Fore Biotherapeuticsfore.bio in 𝕏

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsHBM Healthcare Investments HBM Partners LG Technology Ventures OrbiMed Pontifax Venture Capital SR One Capital Management +4 more

Forendo Pharmaforendo.comSeries A · Oct 2014 · $15M

Co-investorsInnovestor Ventures M Ventures Sunstone Capital

FoRx Therapeuticsforxtherapeutics.com inSeed · Apr 2020 · $11M

FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.

BiotechDeep TechHealthtechBasel, CH

Tarig Bashir(Chief Executive Officer (CEO))inJens Würthner(Chief Medical Officer (CMO))Frank Zenke(Chief Scientific Officer (CSO))in

Co-investorsM Ventures Pfizer Venture Investments Omega Funds

Immunitas Therapeuticsimmunitastx.com inAug 2021

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

Board Laura Brass(Director)in Kai Wucherpfennig(Director)

Co-investorsAgent Capital DC Investment Partners Lifelink Longwood Fund Medical Excellence Capital Ono Venture Investment, Inc.+5 more

Kynexiskynexistx.com in 𝕏

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)Christer Köhler(Founding Director)inKees Been(Chief Executive Officer)in Jens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYsios Capital Forbion Sunstone Capital

LoQus23loqus23.com inSeed · Nov 2021 · $9M

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)in Caroline Benn(Co-founder & CSO)in

Co-investorsDementia Discovery Fund SV Health Investors Forbion

Macrolide Pharmaceuticals inApr 2018 · $20M

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)Henry Skinner(Director)inVikas Goyal(Director)Raj Parekh(Director)in

Co-investorsAdvent Life Sciences Gurnet Point Capital Roche Venture Fund

Nabriva Therapeuticsnabriva.comSeries B · Apr 2015 · $120M

BiotechDublin 1

Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)

Co-investorsAisling Capital EcoR1 Capital Frazier Life Sciences Longitude Capital MESA VERDE VENTURE PARTNERS

Peptonepeptone.io in

Peptone develops a product engine to design small-molecule drug candidates targeting intrinsically disordered proteins, which have been difficult to address with conventional drug discovery approaches.

AI & Machine LearningBiotechDeep Tech

Kamil Tamiola(Founder)

Co-investorsBessemer Venture Partners Hoxton Ventures Walden Catalyst F-Prime Capital Founders Factory Founders Factory NY

Protegoprotegosolutions.io 𝕏Defunct

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

Pablo Rojas(Founder)inRafael Casabianca

Co-investorsY Combinator Digitalis Ventures Droia Ventures Forbion Glilot Capital Partners Global Founders Capital +7 more

Protego Biopharmaprotegobio.com inDec 2025 · $130M

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDroia Ventures Digitalis Ventures Forbion Lightspeed Venture Partners MPM BioImpact Vida Ventures +1 more

Rapptarappta-therapeutics.comOct 2020

Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsAdvent Life Sciences Novo Holdings

Renovacorrenovacorinc.com in

BiotechGreenwhich, US

Wendy DiCicco(Ms. DiCicco is the Secretary and Treasurer of the Issuer.)inArthur Feldman(Director)Magdalene Cook(Executive Officer, Director)Campbell Murray(Director)Edward J. Benz, Jr.(Director)Thomas Needham(Director)in

Co-investorsBioAdvance Broadview Ventures Elysia Capital Innogest Capital New Leaf Venture Partners

Ribon Therapeuticsribontx.com inJan 2019 · $65M

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)in

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAvego BioScience Capital OUP (Osage University Partners)Peregrine Ventures AbbVie Deerfield Management Company JJDC +3 more

Salvinasip-baselarea.com in 𝕏

PSS Solutions is an independent consulting and advisory group focused on intellectual property, helping organizations improve and manage their IP operations.

BiotechEnterprise SoftwareLegalTechPropTech

Sidewinder Therapeuticssidewinderbio.com in

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

BiotechHealthtechMedical DevicesSan Diego, US

Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in

Co-investorsAstellas Venture Management LLC DCVC (Data Collective)DCVC Bio Frazier Life Sciences Longwood Fund OrbiMed +2 more

Tagworks Pharmaceuticalstagworkspharma.com in 𝕏Series A · Jun 2023 · $65M

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBif Lightstone Ventures New Enterprise Associates (NEA)Ysios Capital Clarus Ventures Gilde Healthcare +1 more

Tephatepha.comMar 2012

HealthtechLexington, US

Simon Williams(Executive Officer, Director)John Hartnett(Executive Officer)

Board Richard B. Emmitt(Director)inEdward M. Giles(Director)Anthony J. Sinskey(Director)

Co-investorsThe Vertical Group

Thesan Pharmaceuticals inFeb 2014

BiotechCarlsbad, US

John Gordon Foulkes(Executive Officer, Director)

BoardMette Agger(Director)Peter Bisgaard(Director)Giovanni Ferrara(Director)Tiba Aynechi(Director)Michael Ross(Director)

Co-investorsSV Health Investors SV Life Sciences

Viametviamet.com

Viamet provides a resource for people to organize questions and conduct research about medical travel, provider verification, care coordination, and health-related travel planning.

Digital HealthHealthtechTravel & HospitalityWellness & Fitness

Co-investorsAstellas Venture Management LLC Hatteras Venture Partners Lilly Ventures Woodford Investment Management

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

ImmPACT Bio USA Inc.ArtiosAutonomic Technologies Cavion CoDa TherapeuticsCovagen AGDiagnoplexExpansion TherapeuticsFundaMental PharmaMerganser Biotech NeurovanceOxagenPharmAbcineRappta TherapeuticsSmall Molecules

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 4

3 IPOs · 1 acquisitions

Adicet BioNASDAQ: ACETAileron TherapeuticsNASDAQ: RNTXBicycleNASDAQ: BCYCCovagen AGacq. by Johnson & Johnson

Portfolio news

latest coverage across their companies

Kynexis Extends Series A to €97 Million to Advance Potential First-in-Class Investigational Medicine for Cognitive Disorders | The Manila Times

Kynexis · manilatimes.net · Aug 19, 2026

FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding

Fore Biotherapeutics · finsmes.com · Jul 8, 2026

Averna Therapeutics Announces Strategic Leadership Expansion

Averna Therapeutics · prnewswire.com · Mar 26, 2026

Pipeline - FoRx Therapeutics

FoRx Therapeutics · forxtherapeutics.com · Feb 16, 2026

Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio

Mediar Therapeutics · prnewswire.com · Jan 7, 2026

LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington's Disease

LoQus23 · finance.yahoo.com · Jan 6, 2026

Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study

Protego Biopharma · prnewswire.com · Dec 1, 2025

€99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | EU-Startups

Artios Pharma · eu-startups.com · Nov 17, 2025

Frequently asked questions

How many investments has Novartis Venture Fund made?: Novartis Venture Fund has 67 tracked investments, 4 of which have exited, including 8 dated in the last 24 months.
What stage does Novartis Venture Fund invest at?: Novartis Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
What is Novartis Venture Fund's typical check size?: Novartis Venture Fund typically writes checks of $5M – $25M.
What sectors does Novartis Venture Fund focus on?: Novartis Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Novartis Venture Fund located?: Novartis Venture Fund is headquartered in Basel, CH.
Does Novartis Venture Fund lead rounds?: Yes, Novartis Venture Fund leads investment rounds.
Who does Novartis Venture Fund co-invest with?: Novartis Venture Fund most often shares deals with Pfizer Venture Investments, SV Health Investors, M Ventures, among 83 tracked co-investors.

Co-investors · 27

Forbion

Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.

Both backed · 11

Amphista Therapeutics Anaveon CatalYm Citryll Enterprise Therapeutics F2G Granite Bio Kynexis LoQus23 Protego Protego Biopharma

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 6

Akouos Artios Pharma Expansion Therapeutics GentiBio HYKU BiosciencesArtios

BioGeneration Ventures

BioGeneration Ventures is a European venture capital firm investing in early-stage biotech, medtech and life sciences companies developing novel therapeutics and medical technologies.

Both backed · 6

CatalYm Citryll Epsilogen RhyGaze AG Soteria Biotherapeutics, Inc.FundaMental Pharma

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 6

Alesta AstronauTX Ltd CoDa Therapeutics Epi Biologics Immunitas Therapeutics Protego Biopharma

$1M – $15M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 5

Anaveon Artios Pharma FoRx Therapeutics Mediar Therapeutics Vivet Therapeutics

$5M – $20M

Roche Venture Fund

Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.

Both backed · 5

Epi Biologics Macrolide Pharmaceuticals Soteria Biotherapeutics, Inc.Splice Bio Vivet Therapeutics

$648K – $3.2M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies aligned with Sanofi's mission of advancing human health.

Both backed · 4

Atalanta Expansion Therapeutics Granite Bio Splice Bio

$5M

Ysios Capital

Ysios Capital is a life sciences venture investor that finances innovative biotech companies developing novel therapies for high unmet medical needs, primarily across Europe and the United States.

Both backed · 4

Kynexis Splice Bio Tagworks Pharmaceuticals Vivet Therapeutics

$5.4M – $21.6M

Advent Life Sciences

Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.

Both backed · 4

Amphista Therapeutics F2G Macrolide Pharmaceuticals Rappta

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 3

Akouos Splice Bio Tagworks Pharmaceuticals

$200K – $40M

EQT Life Sciences

EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.

Both backed · 3

Artios Pharma Atalanta Splice Bio

$11M – $66M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 3

Artios Pharma F2G Mediar Therapeutics

$540K – $27M

▶15 more co-investors

Frazier Healthcare Partners Andera Partners Omega Funds GV (Google Ventures)SR One Capital Management Deerfield Management Company DCVC (Data Collective)Atlas Venture Sofinnova Ventures Seventure Partners Inkef Lightstone Ventures 3B Future Health Fund Bayern Kapital Clarus Ventures

Firms observed investing alongside Novartis Venture Fund, from public investor directories. Shared companies are the overlap with Novartis Venture Fund's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.